Enovis (NYSE:ENOV) Director Buys $25,084.36 in Stock

Key Points

• Director Angela Lalor bought 887 Enovis shares for $25,084.36 at an average price of $28.28, increasing her stake by 2.82% to 32,373 shares.
• Enovis reported quarterly EPS of $0.88, beating the $0.77 consensus estimate, while revenue of $558.73 million slightly exceeded forecasts and rose 1.8% year over year.
• Shares fell 3.2% in Thursday mid-day trading to $27.63. Analysts’ consensus rating was “Moderate Buy,” with an average price target of $38.62.

Enovis Corporation (NYSE:ENOV - Get Free Report) Director Angela Lalor acquired 887 shares of the company's stock in a transaction that occurred on Tuesday, November 10th. The stock was bought at an average price of $28.28 per share, with a total value of $25,084.36. Following the acquisition, the director directly owned 32,373 shares of the company's stock, valued at $915,508.44. The trade was a 2.82% increase in their position. The purchase was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink.

Enovis Trading Down 3.2%

NYSE:ENOV traded down $0.92 during mid-day trading on Thursday, hitting $27.63. The company had a trading volume of 1,153,270 shares, compared to its average volume of 1,886,113. The company has a debt-to-equity ratio of 0.82, a quick ratio of 1.08 and a current ratio of 2.15. Enovis Corporation has a fifty-two week low of $16.70 and a fifty-two week high of $31.81. The firm has a market cap of $1.59 billion, a P/E ratio of -3.00 and a beta of 1.31. The business's fifty day moving average is $20.36 and its two-hundred day moving average is $23.19.

Enovis (NYSE:ENOV - Get Free Report) last posted its earnings results on Thursday, November 5th. The company reported $0.88 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.77 by $0.11. The company had revenue of $558.73 million during the quarter, compared to analyst estimates of $557.12 million. Enovis had a positive return on equity of 13.23% and a negative net margin of 22.86%. The company's revenue for the quarter was up 1.8% compared to the same quarter last year. During the same period in the previous year, the company earned $0.75 EPS. As a group, research analysts expect that Enovis Corporation will post 3.15 earnings per share for the current year.

Institutional Trading of Enovis

Large investors have recently bought and sold shares of the business. Allworth Financial LP raised its holdings in Enovis by 59.7% during the 2nd quarter. Allworth Financial LP now owns 1,744 shares of the company's stock worth $36,000 after buying an additional 652 shares during the period. IFP Advisors Inc boosted its holdings in shares of Enovis by 5,590.5% in the second quarter. IFP Advisors Inc now owns 1,195 shares of the company's stock valued at $25,000 after buying an additional 1,174 shares during the period. Inspire Investing LLC boosted its holdings in shares of Enovis by 4.9% in the third quarter. Inspire Investing LLC now owns 34,833 shares of the company's stock valued at $636,000 after buying an additional 1,631 shares during the period. Amundi increased its position in shares of Enovis by 2.3% during the first quarter. Amundi now owns 74,184 shares of the company's stock worth $1,688,000 after acquiring an additional 1,677 shares in the last quarter. Finally, Handelsbanken Fonder AB increased its position in shares of Enovis by 9.3% during the second quarter. Handelsbanken Fonder AB now owns 21,117 shares of the company's stock worth $437,000 after acquiring an additional 1,800 shares in the last quarter. 98.45% of the stock is owned by institutional investors.

Wall Street Analyst Weigh In

Several research analysts recently weighed in on the stock. Zacks Research raised shares of Enovis from a "strong sell" rating to a "hold" rating in a research note on Wednesday, July 29th. Citizens Jmp cut their target price on shares of Enovis from $55.00 to $47.00 and set a "market outperform" rating on the stock in a report on Wednesday, September 2nd. UBS Group restated a "buy" rating and issued a $44.00 price objective on shares of Enovis in a research report on Monday, October 5th. Wall Street Zen raised Enovis from a "hold" rating to a "buy" rating in a research note on Saturday, October 31st. Finally, Citigroup reaffirmed a "market outperform" rating on shares of Enovis in a research note on Wednesday, September 2nd. Ten research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, the company currently has an average rating of "Moderate Buy" and a consensus target price of $38.62.

Enovis Company Profile

Enovis is a medical technology company that develops products and solutions for orthopedic care, surgery, recovery and rehabilitation. Its offerings include joint replacement implants, foot and ankle products, surgical instruments, orthopedic braces and supports, and rehabilitation equipment. The company serves healthcare providers and patients in markets around the world. Its products are designed to support treatment across different stages of musculoskeletal care, from surgical intervention to recovery and mobility.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.